Abbott Laboratories (NYSE: ABT) reported its financial results for the quarter ended March 31, 2020 today.
The company reported a 16% drop in earnings for the first quarter of 2020 due to tax expense despite a 2.5% increase in the top-line. Abbott is suspending its previously announced annual guidance for 2020 due to uncertainties regarding the duration and impact of the coronavirus (COVID-19) pandemic.
Abbott launched three critical new tests for COVID-19, two molecular tests and one serology blood test for the detection of the antibody. While molecular testing detects whether someone has the virus, antibody tests determine if someone was previously infected.
Earlier we looked into how, during the COVID-19 pandemic, retailers saw changing trends in terms of their assortments and how the acceleration of online shopping led many of them to
Data is at the heart of business innovation. Recognizing this trend, companies are seeking ways to transform their businesses by capturing, analyzing, and mobilizing data. The public cloud is becoming
The second half has been highly rewarding for design software maker Adobe Inc. (NASDAQ: ADBE) amid stable demand for digital content solutions. The company has remained unaffected by the virus-related